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Anatomical heterogeneity of Alzheimer
disease
Based on cortical thickness on MRIs
ABSTRACT
Objective: Because the signs associated with dementia due to Alzheimer disease (AD) can be het-
erogeneous, the goal of this study was to use 3-dimensional MRI to examine the various patterns
of cortical atrophy that can be associated with dementia of AD type, and to investigate whether
AD dementia can be categorized into anatomical subtypes.
Methods: High-resolution T1-weighted volumetric MRIs were taken of 152 patients in their earlier
stages of AD dementia. The images were processed to measure cortical thickness, and hierarchi-
cal agglomerative cluster analysis was performed using Ward’s clustering linkage. The identified
clusters of patients were compared with an age- and sex-matched control group using a general
linear model.
Results: There were several distinct patterns of cortical atrophy and the number of patterns varied
according to the level of cluster analyses. At the 3-cluster level, patients were divided into (1)
bilateral medial temporal–dominant atrophy subtype (n 5 52, ;34.2%), (2) parietal-dominant
subtype (n5 28,;18.4%) in which the bilateral parietal lobes, the precuneus, along with bilateral
dorsolateral frontal lobes, were atrophic, and (3) diffuse atrophy subtype (n 5 72, ;47.4%) in
which nearly all association cortices revealed atrophy. These 3 subtypes also differed in their
demographic and clinical features.
Conclusions: This cluster analysis of cortical thickness of the entire brain showed that AD demen-
tia in the earlier stages can be categorized into various anatomical subtypes, with distinct clinical
features. Neurology® 2014;83:1936–1944
GLOSSARY
AD 5 Alzheimer disease; CDR 5 Clinical Dementia Rating; D 5 diffuse atrophy subtype; EOAD 5 early-onset Alzheimer
disease; FP 5 frontoparietal subtype; FT 5 frontotemporal subtype; LP 5 left parietal–dominant subtype; MF 5 medial
frontal/temporal subtype;MT 5medial temporal subtype; NC 5 normal cognition; P5 parietal-dominant subtype; RP 5 right
parietal–dominant subtype.
The clinical presentation of dementia due to Alzheimer disease (AD) is heterogeneous.1–6
Neuropathologic studies have suggested that there are 3 distinct pathologic subtypes in terms
of distribution of amyloid plaques and neurofibrillary tangles.7 Pathologic findings from autop-
sied cases are the gold standard for investigating anatomical heterogeneity; however, the autopsy
findings usually represent advanced stages of the disease, and cannot map the entire brain
because of region-of-interest–based methods. Instead, imaging studies that incorporate a large
number of patients assessing the entire cerebral cortex may demonstrate anatomical heteroge-
neity of AD dementia–induced degeneration at the earlier stages.
To our knowledge, only a few imaging studies have investigated the structural heterogeneity
of AD dementia. A voxel-based morphometry study classified 40 patients into 4 subgroups
according to atrophy patterns in the medial temporal, posterior lateral cortices, and posterior
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cingulate–precuneus.8 However, there have
been no reports of anatomical subgroups for
AD dementia using surface-based morphome-
try, a sensitive method that measures actual
cortical thickness across the entire cortical man-
tle using 3-dimensional MRIs.9 The objective
of this study was to examine variability in
surface-based morphometry cortical atrophy
patterns of the entire cerebral cortex and then
use cluster analyses to determine whether AD
dementia can be categorized into distinct ana-
tomical subgroups. As this disease progresses,
the left-right hemispheric functional and
degenerative asymmetries decrease10,11 and the
cortical degeneration becomes widespread.
Therefore, this study only included participants
who were in their early stages of AD dementia.
METHODS Participants. Of 296 patients with AD dementia
who were evaluated at Samsung Medical Center’s Memory Dis-
orders Clinic from June 2006 to December 2010 and completed
neuropsychological tests as well as high-resolution 3.0-tesla
T1-weighted MRI, we excluded all patients with a Clinical
Dementia Rating (CDR)–Sum of Boxes $5. We also excluded
patients with familial AD of the autosomal-dominant inheritance
type. The final study population therefore consisted of 152
patients with AD dementia with global CDR of 0.5 to 1 and
CDR–Sum of Boxes #4.5.2,12,13
All patients underwent detailed clinical interviews before their
neurologic examinations and neuropsychological tests were con-
ducted. Two fellowship trained behavioral neurologists (S.W. Seo
and D.L. Na) made a diagnosis of probable AD dementia using
the criteria outlined by NINCDS-ADRDA (National Institute of
Neurological and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association).14 Labora-
tory tests were conducted to rule out other causes of dementia, and
included complete blood counts, vitamin B12, folate levels, a
metabolite profile, thyroid function tests, and syphilis serology.
Patients were excluded if they had a cerebral, cerebellar, or brain-
stem infarction, hemorrhage, tumors, hydrocephalus or severe cere-
bral white matter hyperintensities (deep white matter$2.5 cm and
caps or band $1.0 cm), or severe head trauma.
We recruited 72 individuals with normal cognition (NC) to
serve as age- and sex-matched controls for the 152 patients with
AD dementia for MRI cluster analyses. The NC controls were all
characterized by the following: (1) no history of neurologic or
psychiatric disorders, (2) normal cognitive function determined
using neuropsychological tests, and (3) a normal activities of daily
living score as determined using the Seoul–Instrumental Activi-
ties of Daily Living test (with a score ,8).15
Standard protocol approvals, registrations, and patient
consents. All patients provided written informed consent and
the study was approved by the institutional review board of
Samsung Medical Center.
Neuropsychological tests. All participants underwent tests
with a standardized neuropsychological battery, the Seoul Neuro-
psychological Screening Battery,16–18 the details of which are
described in appendix e-1 on the Neurology® Web site at
Neurology.org.
Image analyses. MRI acquisition. Brain MRIs were acquired
using a 3.0-tesla MRI scanner (Achieva; Philips Medical Systems,
Best, the Netherlands) including 3-dimensional T1-weighted
images, as has been described in our previous study.19
Measurements of cortical thickness. T1-weighted images
were processed using an automated anatomical pipeline for
measuring cortical thickness, as described previously.20 Details for
cortical thickness measurements are described in appendix e-2.
Cluster analyses. Cluster analyses were performed using the
whole-brain cortical thickness for each of the 152 patients with
AD dementia. A total of 78,570 vertex points from each
subject were used in the analyses after removing noncortical
regions on the surface model. To cluster patients according to
the relative involvement of each cortical region, rather than
global atrophy alone, the variations in global atrophy between
patients were compensated by normalizing the vertices to mean
cortical thickness.21 Ward’s clustering linkage method21,22 was
used to combine pairs of clusters at each step while minimizing
the sum of square errors from the cluster mean. Each of the 152
patients with AD dementia was placed in their own cluster and
then progressively clustered with others. The cluster analysis
results are shown as a dendrogram (figure 1).
Statistical analyses. A detailed description for statistical
analyses is included in appendix e-3. All statistical analyses
were conducted using PASW Statistics 18 software (SPSS Inc.,
Chicago, IL).
To estimate the anatomical differences between AD dementia
subtypes and NC, the general linear model and random field
theory were applied using the SurfStat toolbox23 (see appendix
e-4 for details). We reported cortical regions reaching a significant
vertex level with random field theory corrected p , 0.05. We
compared cortical atrophy patterns of AD dementia subtypes
with each other using the same method as above.
To provide validation for the clustering, principal component
analysis was used, which is a multivariate method that can be used
to detect correlations in a set of variables. It involves the acquisi-
tion of a set of basis vectors with a linear combination that can
represent the measured data optimally.24 We chose the first
2 principal components, which can be explicated as the optimal
reflection of the full data, showing the highest variability.21
RESULTS AD dementia subtypes identified by cluster
analyses. At the 3-cluster level (figure 2A), the patients
were divided into the following: (1) medial temporal
subtype (MT subtype, n5 52,;34.2%) in which the
bilateral medial temporal lobes were predominantly
involved with additional involvement of anterior and
posterior cingulate cortices; (2) parietal-dominant
subtype (P subtype, n 5 28, ;18.4%) in which the
bilateral parietal areas, precuneus, and bilateral
dorsolateral frontal areas were involved, with little
involvement of medial temporal areas; and (3) diffuse
atrophy subtype (D subtype, n 5 72, ;47.4%) in
which nearly all association cortical areas were
involved except for the orbitofrontal and occipital areas.
At the 4-cluster level (figure e-1A), the MT sub-
type (n 5 52, 34.2%) and the P subtype (n 5 28,
;18.4%) that were identified at the 3-cluster level
were unchanged. D subtype, however, was subdi-
vided into 2 subtypes: the medial frontal/temporal
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subtype (MF subtype) in which the bilateral superior
frontal gyrus and medial temporal areas were domi-
nantly involved (n 5 33, ;21.7%); and the D sub-
type (n 5 39, ;25.7%).
At the 5-cluster level (figure e-1B), the MT (n 5
52, ;34.2%), P (n 5 28, ;18.4%), and MF (n 5
33, ;21.7%) subtypes identified at the 4-cluster level
were unchanged. D subtype was subdivided into the
frontoparietal subtype (FP subtype, n5 31,;20.4%)
and the frontotemporal subtype (FT subtype, n 5 8,
;5.3%). The FP subtype involved the frontal and
parietal areas diffusely. The FT subtype involved the
temporal and inferior parietal area, and partially
involved the frontal area.
Finally, at the 6-cluster level (figure 2B), the MT
(n5 52,;34.2%), MF (n5 33,;21.7%), FP (n5
31, ;20.4%), and FT (n 5 8, ;5.3%) subtypes
were unchanged. The P subtype, however, was
divided according to interhemispheric asymmetry:
the left parietal–dominant subtype (LP subtype) in
which the left inferior parietal, lateral temporal, and
lateral frontal areas were dominantly involved, with
relative sparing of the medial temporal area (n 5 10,
;6.6%); and the right parietal–dominant subtype
(RP subtype) in which the right parietal, lateral tem-
poral, and lateral frontal areas were dominantly
involved (n5 18,;11.8%). Comparisons of cortical
thickness among the 6 AD dementia subtypes con-
firmed that these subtypes were reliably distinguished
(figure e-2).
Principal component analyses. Details on how these
subtypes were identified via principal component
analyses are described elsewhere (figure e-3 and
appendix e-5). The 3 subtypes identified via principal
component analyses are presented in figure e-3.
Demographic and clinical characteristics among 3
subtypes of AD dementia. The demographics of the 3
AD dementia subtypes and the NC group were com-
pared (table 1). Among the 3 subtypes, patients in P
subtype were the youngest, had the youngest age at
onset, and had the highest number of education years.
Meanwhile, patients in D subtype had the lowest
mean cortical thickness (table 1).
Cognitive characteristics among 3 subtypes of AD
dementia. To compare the neuropsychological test
results, we used standard scores (z scores) because the
age, sex, and education years were different among the
AD dementia subtypes. The z scores were derived
based on age- and education-adjusted norms.18
Compared with patients in other subtypes, those
in P subtype scored the worst on most tests except
for language function (table 2).
Comparisons of subtypes at the 6-cluster level are
presented in appendix e-6 and tables e-1 and e-2.
Figure 1 Dendrogram created by cluster analysis of cortical thickness
The distance along the x-axis represents the measure of similarity between patients, such
that the shorter the distance, the greater the similarity between patients. The blue and
red lines represent the clustered 3 or 6 subtypes of AD dementia, which are illustrated in
figure 2. AD5 Alzheimer disease; D5 diffuse atrophy subtype; FP5 frontoparietal subtype;
FT 5 frontotemporal subtype; LP 5 left parietal–dominant subtype; MF 5 medial frontal/
temporal subtype; MT5medial temporal–dominant subtype; P5 parietal-dominant subtype;
RP 5 right parietal–dominant subtype.
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Each subgroup of D subtype showed significantly
different demographic and cognitive characteristics
in comparison with other AD dementia subtypes
(appendix e-7).
DISCUSSION Our major finding is that AD demen-
tia is an anatomically heterogeneous disease and may
not be one disease. The cluster analysis based on cor-
tical atrophy patterns showed that patients diagnosed
with AD dementia can be categorized into anatomi-
cally different subtypes, with 3 to 6 subtypes accord-
ing to the level of clustering. We further identified
some demographic and clinical differences among
these AD dementia subtypes in accordance with
structural differences.
At the 3-cluster level, we identified MT, P, and D
subtypes. Although we limited the analysis to patients
in earlier stages of the disease, these results were largely
in line with a recent pathologic study that identified 3
AD dementia subtypes based on the distribution and
density of neurofibrillary tangles.7 The 3 subgroups
from the pathology study were limbic-predominant
(14.3%), hippocampal-sparing (10.9%), and typical
AD (74.8%),7 which may respectively correspond to
MT subtype (34.2%), P subtype (18.4%), and D sub-
type (47.4%) in our study. The frequency of typical
presentation in our study (D subtype, 47.4%), how-
ever, was lower compared with the previous pathology
study (74.8%). This discrepancy may be attributable
to different disease stages between the 2 studies. We
presume that some patients withMT subtype in earlier
stage may lose the distinctive pattern and become D
subtype as disease progresses.
Among the 3 subtypes, patients in the P subtype
had distinct demographic and clinical features. They
were younger (57.1 6 7.84 years) at the age at onset
than the other 2 subtypes (D: 72.2 6 6.37; MT:
69.86 7.77) and the sex proportion was nearly equal
(female percentage: 53.6%) as opposed to the other
2 subtypes in which women outnumbered men
Figure 2 Statistical maps of cortical atrophy in each of the 3 (A) or 6 (B) subtypes
These subtypes were identified from cluster analysis compared with controls (corrected for multiple comparisons using ran-
dom field theory [RFT] at a vertex-wise significance level of p, 0.05). The results show the relationship between the 3 and
6 subtypes.
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Table 1 Demographic and clinical characteristics of the study population
NC (n 5 72) AD dementia (n 5 152) p Valuea
AD subtypes (n 5 152)
p ValuebMT subtype (n 5 52) P subtype (n 5 28) D subtype (n 5 72)
Age at MRI, y 71.3 6 5.76 71.8 6 8.90 0.636 72.9 6 7.49c 60.4 6 7.88d,e 75.5 6 6.19c ,0.001f,g
Age at onset, y — 68.6 6 9.04 69.8 6 7.77c 57.1 6 7.84d,e 72.2 6 6.37c ,0.001f,g
Sex, female, n (%) 51 (70.8) 101 (66.4) 0.512 38 (73.1) 15 (53.6) 48 (66.7) 0.211h
Education, y 9.84 6 4.51 9.35 6 5.65 0.485 8.40 6 5.42b 12.4 6 4.30a,c 8.86 6 5.94b 0.006f,g
Ds duration, mo — 38.8 6 21.58 36.9 6 20.4 39.1 6 19.5 40.0 6 23.3 0.737f
ICV, cm3 1.34 3 106 6 1.21 3 105 1.32 3 106 6 1.19 3 105 0.492 1.32 3 106 6 1.25 3 105 1.36 3 106 6 1.22 3 105 1.32 3 106 6 1.12 3 105 0.216f
Mean CTh 3.02 6 0.11 2.85 6 0.13 ,0.001g 2.91 6 0.13c 2.86 6 0.12 2.81 6 0.13a ,0.001f,g
APO e4 genotype, n (%) 10/49 (20.4) 55/123 (44.7) 0.003g 20/42 (47.6) 6/24 (25.0) 29/57 (50.9) 0.091h
K-MMSE 28.6 6 1.23 21.0 6 3.94 ,0.001g 21.5 6 3.88 21.5 6 3.33 20.5 6 4.18 0.347
CDR-SB 0 3.34 6 0.89 3.20 6 0.90 3.18 6 0.94 3.50 6 0.86 0.108
Abbreviations: AD 5 Alzheimer disease; CDR-SB 5 Clinical Dementia Rating–Sum of Boxes; CTh 5 cortical thickness; D subtype 5 diffuse atrophy subtype; Ds 5 disease; ICV 5 intracranial volume; K-MMSE 5
Korean version of Mini-Mental State Examination; MT subtype 5 medial temporal–dominant subtype; NC 5 normal control; P subtype 5 parietal-dominant subtype.
Data are presented as mean 6 SD. CDR-SB scored out of 18; K-MMSE scored out of 30.
a The p value for the comparison between the AD dementia and control groups.
b The p value for the comparison across the three AD subtypes.
cSignificant difference (p , 0.05) between P subtype and the other subtypes.
dSignificant difference (p , 0.05) between MT subtype and the other subtypes.
eSignificant difference (p , 0.05) between D subtype and the other subtypes.
f Analysis of variance followed by Bonferroni post hoc test was used.
gSignificant p values (,0.05).
h The x2 test was used.
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(D: 66.7%; MT: 73.1%). The proportion of females
with hippocampal-sparing AD (37%) was also lower
than for limbic-predominant AD (69%) in the path-
ologic study.7 Although the P subtype appeared to
have lower APO e4 frequency than the other sub-
types, this difference did not reach statistical signifi-
cance. Previous studies have demonstrated that
patients with early-onset AD (EOAD) seldom carry
the APO e4 allele.7,25
Our patients with P subtype had a distinct clinical
phenotype regarding cognitive deficit profile with atten-
tion, visuospatial, and frontal-executive functions being
significantly impaired in comparison to the other 2 sub-
types. These neuropsychological findings may be consis-
tent with the observed cortical thinning in patients with
P subtype that predominantly affected bilateral parietal
cortices, precuneus, and dorsolateral frontal cortices.
Decreased attention in our patients with P subtype
may be associated with dorsolateral prefrontal and pari-
etal dysfunction, and visuoconstructive deficits may
primarily be attributed to cortical thinning in parietal
areas. The precuneus is known to be associated with a
broad range of highly integrated tasks, such as executive
function, retrieval of episodic memory, visuospatial
imagery, and self-processing operations.26–28 We there-
fore assume that the precuneus damage in our patients
with P subtype might have also contributed to their
impaired attention, visuospatial function, and executive
function. Because the medial temporal area was rela-
tively spared in the P subtype, we expected that perfor-
mance on tests of episodic memory would be better in
this type than in the other subtypes. Contrary to our
expectations, however, all scores for memory function
tests were also the worst in patients with P subtype. It is
possible that memory deficits in these patients may
be associated with deficits in attention and working
memory, which are related to dorsolateral prefrontal
and parietal dysfunction. Alternatively, precuneus
damage or its extension to the retrosplenial region (see
figure 2), which has been demonstrated to be important
Table 2 Neuropsychological test results
AD subtypes
p ValueMT subtype (n 5 52) P subtype (n 5 28) D subtype (n 5 72)
Attention
Digit Span Forward 20.34 6 1.15 20.48 6 1.02 20.22 6 0.96 0.515
Digit Span Backward 20.46 6 1.13a 21.18 6 0.88b 20.69 6 1.02 0.014c
Language and related function
K-BNT 22.64 6 2.60 23.87 6 3.63 22.86 6 2.46 0.157
Visuospatial function
RCFT copy 21.04 6 1.90a 25.77 6 5.82b,d 21.90 6 2.25a ,0.001c
Memory
SVLT, immediate recall 21.32 6 0.83a 22.26 6 1.25b,d 21.51 6 0.84a ,0.001c
SVLT, delayed recall 22.08 6 0.79a 22.71 6 0.91b,d 21.96 6 0.79a ,0.001c
SVLT, recognition 21.95 6 1.21a 23.11 6 2.39b,d 21.82 6 1.39a 0.001c
RCFT, immediate recall 21.51 6 0.59a 22.29 6 0.81b,d 21.53 6 0.72a ,0.001c
RCFT, delayed recall 21.69 6 0.68a 22.28 6 0.92b,d 21.68 6 0.68a 0.001c
RCFT, recognition 21.63 6 0.98 22.15 6 1.59d 21.37 6 1.14a 0.018c
Frontal executive function
COWAT, semantic fluency–animals 21.12 6 0.94 21.46 6 0.87 21.07 6 1.12 0.226
COWAT, semantic
fluency–supermarket items
20.90 6 0.83a 21.64 6 0.76b,d 21.04 6 0.83a 0.001c
COWAT, phonemic fluency
with 3 letters
20.62 6 0.94a 21.29 6 1.00b 20.97 6 0.86 0.011c
Stroop test, color reading 21.20 6 1.20a 23.89 6 1.94b,d 21.52 6 1.31a ,0.001c
Abbreviations: AD 5 Alzheimer disease; COWAT 5 Controlled Oral Word Association Test; D subtype 5 diffuse atrophy
subtype; K-BNT 5 Korean version of Boston Naming Test; MT subtype 5 medial temporal–dominant subtype; P subtype 5
parietal-dominant subtype; RCFT 5 Rey–Osterrieth Complex Figure Test; SVLT 5 Seoul Verbal Learning Test.
Data are shown as mean 6 SD. All data are z scores. Analysis of variance followed by Bonferroni post hoc test was used.
aSignificant difference (p , 0.05) between P subtype and the other subtypes.
bSignificant difference (p , 0.05) between MT subtype and the other subtypes.
c Significant p values (p , 0.05).
dSignificant difference (p , 0.05) between D subtype and the other subtypes.
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in episodic memory, may have also contributed to the
memory impairment.29 In summary, our patients with
P subtype are largely in line with patients with EOAD
who show predominant parietal symptoms and signs,30
disproportionate atrophy in the precuneus compared
with late-onset AD,31 and the hippocampal-sparing
group seen in a pathologic study.7
Our P subtype was further divided into LP and RP
subtypes; these 2 subtypes showed differences in neu-
ropsychological test performance. Patients with LP
subtype had lower scores on tests that demand lan-
guage function such as naming, verbal memory, and
oral word fluency. However, the patients with RP
subtype performed worse on visuospatial function
tests. These findings are in line with previous reports
of left-right asymmetries: greater leftward asymmetry
for neurofibrillary tangles or cortical atrophy is
observed in the aphasic phenotype,6,32 whereas greater
hypometabolism on the right side is associated with
visuospatial dysfunction.1,10 In addition, it may be
possible that an extreme form of LP subtype may
represent logopenic progressive aphasia whereby pa-
tients present with progressive language disturbance,
which is similar to the conduction aphasia associated
with strokes in the region of the inferior parietal lobe.
Anatomical substrates for logopenic aphasia localize
mainly to the left temporal–parietal junction with
additional left dorsolateral prefrontal regions,33 which
largely overlap the lesions of our LP subtype.
Our P subtype may not follow Braak staging,
because parietal and frontal cortices are known to
be regions where amyloid deposition may occur only
in later stages (stage V). However, a previous report
suggested that the origin and spread of pathology in
AD cases does not always follow Braak staging.7 They
also demonstrated that the cortical atrophy patterns
on MRI differed among the pathologic subtypes of
AD dementia.34
In contrast to patients with P subtype, patients
with MT subtype were older and predominantly
women (73.1%), with a higher frequency of APO
e4 allele carriers (MT vs p 5 47.6% vs 25.0%). This
sex difference might result from age-related reduc-
tions in sex hormone (estrogen). Estrogen is known
to increase neurogenesis in the hippocampus, and an
alteration in the response of the hippocampus to
estrogen may cause age-related changes in the female
brain.35,36 Second, a preclinical study showed that
APO e4 affects the brains of women more than
men.37 At the same time, APO e4 may have regionally
specific effects in the medial temporal lobe.38 There-
fore, in the elderly AD population, women more than
men may have a more vulnerable medial temporal
cortex, resulting in the MT subtype.
The MT subtype shares several clinical character-
istics with subtypes from studies that were labeled
as limbic neurofibrillary tangle dementia,39 tangle-
predominant dementia,40 or limbic-predominant
AD.7 These subsets of late-onset AD are associated
with older age and female predominance, in which
neurofibrillary tangles were predominant in the allo-
cortical regions with few isocortical tangles.7,39,40
Patients with MT subtype also had cortical thinning
in the anterior and posterior cingulate cortices. There-
fore, we presume that the involvement of the poste-
rior cingulate–retrosplenial cortex, along with medial
temporal lesions, contributes to memory dysfunction
in these patients. Although the anterior cingulate cor-
tex is associated with the expectation of tasks, atten-
tion, modulation of emotion, and motivation, its role
in the behavioral manifestations of this MT subtype
needs to be further clarified.
Patients with D subtype were the oldest and had
the lowest mean cortical thickness among the 3 sub-
types. The level of female predominance was between
the ranges of the other 2 subtypes. The proportion of
patients carrying the APO e4 allele was higher than
the P subtype, but similar to the MT subtype. The
neuropsychological profiles of the D subtype were not
significantly different from those of the MT subtype.
This subtype may be compatible with typical AD
dementia, as observed in a pathologic study.7
In conclusion, based on cortical thickness meas-
urements, it appears that there are at least 3 major
subtypes of AD dementia: (1) the parietal-dominant
atrophy, younger onset, equal sex, low APO e4 sub-
type; (2) the medial temporal/cingulate-dominant
atrophy, older onset, female dominance, high APO
e4 subtype; and (3) the diffuse atrophy subtype with
characteristics in between. It is possible that with a
larger group of participants, a total of 4 to 6 distinc-
tive subtypes could be characterized based on patterns
of atrophy. Consideration of this heterogeneity in the
patterns of atrophy and the associated neurobehavio-
ral decrements may be important when planning
future preventative and treatment strategies, because
the subtypes described in this study may have
different responses to treatment. In addition, these
subtypes may have different courses of disease pro-
gression. Because P subtype was similar to EOAD in
demographics and cognitive function, we presume
the disease progression of P subtype may follow the
pattern of EOAD. Previous studies have revealed
that typically EOAD has a rapid cognitive decline
with rapidly occurring cortical atrophy.19,30 In
contrast, MT subtype, which is similar to limbic-
predominant late-onset AD, may have a slower cog-
nitive decline with slower cortical thinning.4,7,19
There are some limitations to this study. First, the
participants were not studied using amyloid-PET
imaging, their CSF was not assayed for b-amyloid
peptides/tau, and postmortem pathologic studies
1942 Neurology 83 November 18, 2014
were not performed. Thus, we cannot completely
exclude the possibility that our sample may include
participants with other forms of dementia. Second,
the younger age of the patients with AD dementia
might alter the relative distribution of subtypes,
because the previous study showed the strong effects
on the proportion of different pathologic subtypes.
Future studies examining these factors may enable a
better understanding of the pathologic basis of these
subtypes.
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